These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10834421)

  • 21. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes.
    Roach P; Strack T; Arora V; Zhao Z
    Int J Clin Pract; 2001 Apr; 55(3):177-82. PubMed ID: 11351771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
    Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
    Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
    Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
    J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal.
    Del Sindaco P; Ciofetta M; Lalli C; Perriello G; Pampanelli S; Torlone E; Brunetti P; Bolli GB
    Diabet Med; 1998 Jul; 15(7):592-600. PubMed ID: 9686700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Treat Endocrinol; 2003; 2(1):71-6. PubMed ID: 15871555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes.
    Valle D; Santoro D; Bates P; Scarpa L;
    Diabetes Nutr Metab; 2001 Jun; 14(3):126-32. PubMed ID: 11476359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
    Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.
    Gale EA
    Diabet Med; 2000 Mar; 17(3):209-14. PubMed ID: 10784225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine.
    Brunetti P; Muggeo M; Cattin L; Arcangeli A; Pozzilli P; Provenzano V; Francesconi A; Calatola P; Santeusanio F
    Nutr Metab Cardiovasc Dis; 2010 Sep; 20(7):519-26. PubMed ID: 19703761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.
    Alemzadeh R; Berhe T; Wyatt DT
    Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study.
    Hartemann-Heurtier A; Sachon C; Masseboeuf N; Corset E; Grimaldi A
    Diabetes Metab; 2003 Feb; 29(1):53-7. PubMed ID: 12629448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.